Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
Year-over-year free cash flow growth rate
Percentile
P51
Within normal range
vs 5Y Ago
-0.5x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -8.44% |
| Q3 2025 | -21.34% |
| Q2 2025 | 3519.60% |
| Q1 2025 | -106.17% |
| Q4 2024 | -33.19% |
| Q3 2024 | 26986.25% |
| Q2 2024 | 101.55% |
| Q1 2024 | 17.45% |
| Q4 2023 | -359.16% |
| Q3 2023 | -122.92% |
| Q2 2023 | 131.09% |
| Q1 2023 | 13.23% |
| Q4 2022 | -62.95% |
| Q3 2022 | -4.78% |
| Q2 2022 | 50.21% |
| Q1 2022 | -35.65% |
| Q4 2021 | -82.14% |
| Q3 2021 | -119.10% |
| Q2 2021 | 373.69% |
| Q1 2021 | -24.57% |
| Q4 2020 | 18.30% |
| Q3 2020 | -40.61% |
| Q2 2020 | -278.22% |
| Q1 2020 | 63.94% |
| Q4 2019 | 31.57% |
| Q3 2019 | 10.57% |
| Q2 2019 | -1672.30% |
| Q1 2019 | -108.17% |
| Q4 2018 | 157.19% |
| Q3 2018 | 26.88% |
| Q2 2018 | -17.32% |
| Q1 2018 | -19.34% |
| Q4 2017 | -11.90% |
| Q3 2017 | 9.33% |
| Q2 2017 | 6.34% |
| Q1 2017 | -66.82% |
| Q4 2016 | 45.36% |
| Q3 2016 | -22.32% |
| Q2 2016 | 17.95% |
| Q1 2016 | -63.24% |